Navigation Links
Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
Date:9/13/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 13 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announces the expansion of therapeutic focused device clinical trial services in India. Max Neeman has formed an experienced and world class team of medical device experts specializing in carrying out cardiac device trials – therapeutic, diagnostic and surgical. Coronary artherectomy, cardiac stents, aneurysm, mitral valve regurgitation and acute coronary syndrome form 90% of the total device trial experience. These are multicentric global trials with patients as high as 300.  Along with prior experience of conducting device trials, the specialized Max Neeman team and services adds an enhanced level of company expertise in conducting simple to complex device studies.  Max Neeman also has medical device operations and regulatory experience in various other device therapeutic areas as well including CNS and Ophthalmology.

India is emerging as a destination of choice for medical device development and conducting device trials as the market for percutaneous coronary interventions has expanded.  India's device market is currently valued at US $1.7 Billion and projected to grow at the rate of 23% annually.  Benefits which have accelerated outsourcing of device trials to India include: shortened product development cycle, faster time to market (by approximately 30% due to faster patient recruitment) and testing resulting in significant cost savings of about 40-50%.  Max Neeman International conducts device studies for small to large device firms across the globe delivering high quality results at a lower cost resulting in high client satisfaction.  

About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 22 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
4. PRA Internationals Drug Safety Experts to Speak at Safety Congress
5. Biosystems International Merges With Microbiochips
6. Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection
7. International Isotopes Inc. Announces Completion of a Licensing and Permitting Assistance Agreement with URENCO USA
8. Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference
9. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
10. /C O R R E C T I O N - Mindray Medical International Limited /
11. Ellman International Announces Executive Team Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):